EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Association Between Chemotherapy Regimens and Neutropenia Severity Among Cancer Patients: A Cross-Sectional Study

Elaf Ali Jamaluldeen, Aula Fadhil Alwan, Rasha Hassan Abdulhussein Al-Oraibi, Mohammed Kamil Al Qayyim, Musaab Kadhim Alabboodi

Middle Eastern Cancer and Oncology Journal · 26.02.2026 · 2 (1) · 41-47

DOI: 10.61706/mecoj160183 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Middle Eastern Cancer and Oncology Journal, online erschienen am 26.02.2026. Verfasst von Elaf Ali Jamaluldeen und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy-induced neutropenia (CIN) is a prevalent and potentially severe complication in cancer patients, significantly increasing the risk of infection, treatment delays, and overall morbidity. Despite its clinical importance, there is a paucity of data regarding the patterns and severity of neutropenia in relation to specific chemotherapy regimens in diverse oncology settings. A cross-sectional study was conducted involving 98 cancer patients diagnosed with neutropenia following chemotherapy at three oncology centers in Iraq. The data were collected retrospectively from the patients' medical records and included demographic characteristics, the number of chemotherapy cycles at the onset of neutropenia, the severity of neutropenia, the status of chemotherapy continuation, and the specific treatment regimens administered. The association between chemotherapy regimens and severity of neutropenia was analyzed using chi-square tests. The majority of patients were female (68.4%) and over 50 years of age (75.5%). Hematological malignancies were predominant (81%). Neutropenia was most frequently observed during the second cycle of chemotherapy (47%) and was typically of moderate severity (68.4%). Notwithstanding the occurrence of neutropenia, the administration of chemotherapy was pursued in 70.5% of cases. The most frequently observed association between the regimen and neutropenia was the Hodgkin lymphoma protocol (doxorubicin, bleomycin, vinblastine, and dacarbazine), which accounted for 14.3% of cases and exhibited a significant association with the severity of neutropenia (p = 0.012). Furthermore, the analysis revealed statistically significant associations between specific regimens and both acute lymphoblastic leukemia (p = 0.031) and non-Hodgkin lymphoma (p = 0.044). This study underscores the critical need for regimen-specific risk assessment and individualized management strategies for neutropenia in cancer patients. The identification of high-risk regimens can inform proactive monitoring and supportive interventions, with the aim of minimizing complications and optimizing treatment continuity.

Zitieren

APA

Jamaluldeen, E. A., Alwan, A. F., Al-Oraibi, R. H. A., Qayyim, M. K. A., & Alabboodi, M. K. (2026). Association Between Chemotherapy Regimens and Neutropenia Severity Among Cancer Patients: A Cross-Sectional Study. Middle Eastern Cancer and Oncology Journal, 2(1), 41-47. https://doi.org/10.61706/mecoj160183

Vancouver

Jamaluldeen EA, Alwan AF, Al-Oraibi RHA, Qayyim MKA, Alabboodi MK. Association Between Chemotherapy Regimens and Neutropenia Severity Among Cancer Patients: A Cross-Sectional Study. Middle Eastern Cancer and Oncology Journal. 2026;2(1):41-47. doi:10.61706/mecoj160183

BibTeX
@article{Jamaluldeen2026,
  author = {Jamaluldeen, Elaf Ali and Alwan, Aula Fadhil and Al-Oraibi, Rasha Hassan Abdulhussein and Qayyim, Mohammed Kamil Al and Alabboodi, Musaab Kadhim},
  title = {Association Between Chemotherapy Regimens and Neutropenia Severity Among Cancer Patients: A Cross-Sectional Study},
  journal = {Middle Eastern Cancer and Oncology Journal},
  year = {2026},
  volume = {2},
  number = {1},
  pages = {41--47},
  doi = {10.61706/mecoj160183}
}
Kostenlos starten →